Trial Profile
A Phase 2 Placebo-Controlled, Double-Blind, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 (Vixotrigine) in Treating Pain Experienced by Subjects With Confirmed Small Fiber Neuropathy That is Idiopathic or Associated With Diabetes Mellitus
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Vixotrigine (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Acronyms CONVEY
- Sponsors Biogen
- 16 Sep 2021 According to Biogen media release, Biogen will further evaluate the CONVEY data and plans to complete a Phase 1 clinical study to inform potential next steps in the development of vixotrigine. In addition, detailed results from this CONVEY study will be made available in a future scientific forum.
- 16 Sep 2021 Primary endpoint (Change from Baseline in Weekly Mean Average Daily Pain (ADP) Score (BIIB074 200 mg vs placebo)) has been met as per Biogen media release.
- 16 Sep 2021 Primary endpoint (Change from Baseline in Weekly Mean Average Daily Pain (ADP) Score (BIIB074 350mg vs placebo)) has not been met as per Biogen media release.